Clinical trials: Single Women
Immunoglobulin A (IgA) Nephropathy
PS-002 for the Treatment of IgA Nephropathy in Adults
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy.
- Trial name
- NCT07182227
- Testing
- PS-002
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Purespring Therapeutics Limited
Renal Failure, Chronic, End-Stage Renal Disease
PK of Serelaxin in Severe Renal Impairment and ESRD
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD)…
- Trial name
- CRLX030A2102 (NCT01875523)
- Testing
- Serelaxin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Stress Urinary Incontinence, Urinary Incontinence
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after…
- Conditions
- Stress Urinary Incontinence, Urinary Incontinence, Mixed Urinary Incontinence
- Trial name
- BASIS (NCT06480227)
- Testing
- Solyx Single-incision Sling, Bulkamid Transurethral Bulking Agent
- Where
- 7 sites in United States
- Volunteers
- 358 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Infertility, Female
Effects of SNP of GnRH Receptor Genes in IVF Patients
Gonadotropin-releasing hormone analogue (GnRH-a) "long protocol" is a protocol for pituitary down-regulation in IVF. However, it is common in clinic that some patients are hypersensitive to pituitary down-regulation and have…
- Trial name
- NCT02979886
- Testing
- GnRH-a, Human Menopausal Gonadotropins
- Volunteers
- 1,500 people
- Sponsor
- Miao benyu
Fatigue, Iron-deficiency
Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue
This study investigates the effect of intravenous iron substitution in non-anaemic premenopausal women with iron deficiency on: Changes in the cerebral Dopamine (DA) receptor density after iron substitution, shown by brain PET…
- Trial name
- NCT03305705
- Testing
- Iron Carboxymaltose, Sodium chloride 0.9%
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Albina Nowak, MD
Locally Advanced Cervical Cancer
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
This is a single-arm, single-center, exploratory study, the purpose of this study is to evaluate the efficacy and safety of envafolimab combined with Chemoradiotherapy in participants with locally advanced cervical cancer.
- Trial name
- NCT05799469
- Testing
- Envafolimab, Cisplatin, External Beam Radiotherapy (EBRT)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing University Cancer Hospital
Breast Cancer
Clinical Study to Assess the Safety and Performance of Kenko Breast AI+ Medical Device as an Aid to Breast Cancer Diagnosis in Adult Women
The goal of this observational study is to learn whether a new medical software tool called Kenko Breast AI+ can help healthcare professionals read breast magnetic resonance imaging (MRI) scans better to help diagnose breast…
- Trial name
- NCT07580105
- Testing
- Kenko Breast AI+
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Kenko Imalytics S.L.
Bladder Cancer, Bladder Neoplasm
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate…
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Tumors, Cancer of Bladder
- Trial name
- RITE-USA (NCT03335059)
- Testing
- Synergo® RITE + MMC
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Medical Enterprises Ltd.
Glomerulonephritis
Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency
The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function.
- Trial name
- NCT05505955
- Testing
- HRS-5965
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Infertility, Female, Infertility
Vitamin D and Polycystic Ovarian Syndrome (PCOS)
Primary Objectives: To evaluate the efficacy of metformin and Vitamin D supplementation on serum insulin and serum androgen levels (Total testosterone, Steroid Hormone Binding Globulin, Free Androgen Index) levels compared…
- Conditions
- Infertility, Female, Infertility, Vitamin D Deficiency
- Trial name
- NCT03989778
- Testing
- Vitamin D
- Where
- 2 sites in Pakistan
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Ovarian Cancer, Serous Ovarian Cancer
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
- Trial name
- NCT05113368
- Testing
- Regorafenib, Fulvestrant
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sarah K. Lynam MD
Breast Neoplasm Female, Lymphatic Metastasis
Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial
The OBSERB study is a multi-center, non-blinded, pragmatic, parallel, randomized controlled trial in which patients with cT1-3N1 and ycN0 breast cancer.
- Trial name
- OBSERB (NCT04116125)
- Testing
- Radiotherapy
- Volunteers
- 1,380 people
- Sponsor
- Kyungpook National University Chilgok Hospital
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Renal Insufficiency
PF-04634817 Renal Impairment Study
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment.
- Trial name
- NCT01791855
- Testing
- PF-04634817
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects
Study to assess the safety and tolerability of COMBIVENT® hydrofluoroalkane (HFA) as compared to COMBIVENT® chlorofluorocarbons (CFC) and placebo HFA after single and repetitive dosing in healthy male and female subjects
- Trial name
- NCT02173678
- Testing
- COMBIVENT® HFA-MDI, COMBIVENT® CFC-MDI
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Overactive Bladder, Voiding Dysfunction
A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
Urinary incontinences is a highly prevalent and distressing condition which has a significant impact on health related quality of life in millions of women worldwide.
- Conditions
- Overactive Bladder, Voiding Dysfunction, Urinary Incontinence
- Trial name
- NCT02297178
- Testing
- Cystoscopy only, Cystoscopy and Urethral dilatation
- Sponsor
- Medway NHS Foundation Trust
Hemodialysis, Hyperuricemia
This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy
Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we…
- Trial name
- NCT07144332
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Infection, Heart Failure
Serum Potassium Prediction Using Machine Learning and Single-lead ECG
This is a retrospective study drawing on data from the Brigham and Women's Hospital Home Hospital Program's Database. Sociodemographic and clinical data from a training cohort were used to train a machine learning algorithm to…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT07493798
- Testing
- Potassium estimation algorithm
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Metastatic Renal Cell Carcinoma (mRCC)
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
- Trial name
- NCT01514448
- Testing
- Everolimus (RAD001)
- Where
- 13 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.